<DOC>
	<DOCNO>NCT01809314</DOCNO>
	<brief_summary>This observational study evaluate efficacy safety epoetin beta ( NeoRecormon ) participant symptomatic anemia cancer receive chemotherapy . Participants receive NeoRecormon weekly accordance Summary Product Characteristics follow 4 month .</brief_summary>
	<brief_title>An Observational Study Epoetin Beta ( NeoRecormon ) Participants With Cancer Receiving Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adults great equal ( â‰¥ ) 18 year age Participants solid tumor lymphoproliferative disease Participants receive chemotherapy Participants erythropoietin indicated prestudy Hb level observe anemic symptom : Hb le ( &lt; ) 11 g/dL 6.83 millimoles per liter ( mmol/L ) ECOG performance status 0 , 1 , 2 Resistant hypertension Acute chronic bleeding within 3 month prior study Iron deficiency unmanageable prior study Hypersensitivity active substance excipients product Pregnant breastfeed woman Epoetin treatment within 6 month prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>